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Myosin II phosphorylation–dependent cell motile events are regulated by myosin light-chain (MLC) kinase and MLC
phosphatase (MLCP). Recent studies have revealed myosin phosphatase targeting subunit (MYPT1), a myosin-binding
subunit of MLCP, plays a critical role in MLCP regulation. Here we report the new regulatory mechanism of MLCP via
the interaction between 14-3-3 and MYPT1. The binding of 14-3-3 to MYPT1 diminished the direct binding between
MYPT1 and myosin II, and 14-3-3 overexpression abolished MYPT1 localization at stress fiber. Furthermore, 14-3-3
inhibited MLCP holoenzyme activity via the interaction with MYPT1. Consistently, 14-3-3 overexpression increased
myosin II phosphorylation in cells. We found that MYPT1 phosphorylation at Ser472 was critical for the binding to 14-3-3.
Epidermal growth factor (EGF) stimulation increased both Ser472 phosphorylation and the binding of MYPT1-14-3-3.
Rho-kinase inhibitor inhibited the EGF-induced Ser472 phosphorylation and the binding of MYPT1-14-3-3. Rho-kinase
specific siRNA also decreased EGF-induced Ser472 phosphorylation correlated with the decrease in MLC phosphoryla-
tion. The present study revealed a new RhoA/Rho-kinase–dependent regulatory mechanism of myosin II phosphorylation
by 14-3-3 that dissociates MLCP from myosin II and attenuates MLCP activity.
INTRODUCTION
Myosin II is an actin-based motor protein that plays a critical
role in diverse cell motile events such as muscle contraction,
cell locomotion, cell division, and the maintenance of cell
morphology. In vertebrate nonmuscle and smooth muscle
cells, myosin II motor function is regulated by phosphory-
lation of the regulatory light chain (MLC; Kamm and Stull,
1989; Sellers, 1991; Tan et al., 1992). Several protein kinases
can phosphorylate myosin II in vitro but physiologically
important kinases are thought to be different among the cells
types. In smooth muscle, Ca2/calmodulin-dependent MLC
kinase (MLCK) is primarily responsible for myosin II phos-
phorylation. In nonmuscle cells, multiple kinases may phos-
phorylate myosin II upon various types of stimulation. On
the other hand, recent studies have revealed that myosin II
phosphorylation is also controlled by regulating the activity
of MLC phosphatase (MLCP).
MLCP holoenzyme consists of three subunits, a myosin-
binding large subunit (MYPT1), a 20-kDa small subunit, and
a catalytic subunit of the type 1 protein serine/threonine
phosphatase family, PP1 (Alessi et al., 1992; Shimizu et al.,
1994; Shirazi et al., 1994). It has been reported that holoen-
zyme has an affinity for myosin (Shimizu et al., 1994) and
shows higher phosphatase activity than the isolated catalytic
subunit (Alessi et al., 1992; Shirazi et al., 1994), suggesting
that the binding of the regulatory subunits increases enzyme
activity presumably related to the myosin-binding activity
of MYPT1. It has been shown that MYPT1 can be phosphor-
ylated by Rho-kinase, resulting in a decrease in MLCP ac-
tivity in vitro (Kimura et al., 1996). Rho-kinase phosphory-
lates MYPT1 at two sites in vitro, i.e., Thr641 and Thr799 (in
rat MYPT1 sequence, corresponds to the Thr696 and Thr853
of human MYPT1, respectively), of which Thr641 is respon-
sible for the inhibition of MLCP activity (Feng et al., 1999).
This raises the hypothesis that an activation of the Rho
signaling pathway could phosphorylate MYPT1 by Rho-
kinase, thus down-regulating MLCP.
The structure–function relationship of MYPT1 has been
studied. Ichikawa et al. (1996) showed that the recombinant
N-terminal two thirds of the large subunit contains a myo-
sin-binding site. On the other hand, it has been reported that
the C-terminal 291 residues of the large subunit, not the
N-terminal fragment, bind to myosin. MYPT1 is critical to
hold the three subunits together. The C-terminal 72 residues
reside at the 21/20 kDa subunit binding site (Johnson et al.,
1997). The catalytic subunit binds to the large subunit at two
sites, a relatively strong site in the N-terminal 38 residues
and a weak site in the ankyrin repeat (residues 39–295;
Hirano et al., 1997). A binding site for phosphorylated MLC
is also assigned to the ankyrin repeat.
Although isolated MLCP/MYPT1 binds strongly to myo-
sin, intracellular localization of MYPT1 is not entirely colo-
calized with myosin filaments, and a significant fraction of
MYPT1 is present throughout cytosol (Murata et al., 1997).
This raises the hypothesis that the association of MYPT1/
MLCP to myosin in vivo is regulated.
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In the present study, we found that 14-3-3 interacts with
MYPT1, using yeast two-hybrid system. 14-3-3 is an acidic
small-molecular-mass protein that is widely expressed in a
variety of organisms, and it is thought that 14-3-3 play a role
in various cellular processes such as signal transduction, cell
cycle regulation, apoptosis, and cytoskeletal reorganization
(Fu et al., 2000; van Hemert et al., 2001; Tzivion and Avruch,
2002; Aitken, 2006), although the function of 14-3-3 is still
not completely understood. Here we report that 14-3-3 binds
to MYPT1 and the binding attenuates MLCP phosphatase
activity and induces dissociation of MYPT1 from myosin.
The overexpression of 14-3-3 in COS7 cells abolished the
localization of MYPT1 at the stress fiber, indicating that
14-3-3 controls the interaction between MLCP and myosin II,
thus regulating myosin II phosphorylation in cells. Further-
more, we found that the phosphorylation of MYPT1 at
Ser472 was critical for the binding to 14-3-3 and Rho-kinase–
activated Ser472 phosphorylation in the epidermal growth
factor (EGF) signaling pathway. The present study uncovers
a new regulatory mechanism of MLCP function and thus the
regulation of myosin II phosphorylation.
MATERIALS AND METHODS
Yeast Two-Hybrid Analysis
Yeast two-hybrid screening was performed as described (Koga and Ikebe,
2005). Briefly, yeast AH109 strains were sequentially transformed with
pGBKT7 coding for full-length rat MYPT1 and then with a human aorta
cDNA library constructed in pACT2. Initial transformants were selected for
being positive on synthetic complete plates lacking tryptophan-leucine-histi-
dine-adenine and containing X--gal on the surface of the plates. Of 3.5
million initial transformants, two clones, termed clones TM27 and TM41,
interacting with MYPT1 were identical.
Vector and cDNA Constructs
The mutants were made by the site-directed mutagenesis strategy (Yano et al.,
1993). To delete the C-terminal residues of MYPT1, a stop codon was created
at codons 39, 172, 297, and 517 for F38, K171, E296 and N516, respectively.
pGBKT7/MYPT1 was digested by NcoI to excise a cDNA fragment encoding
amino acids 1–376 of rat MYPT1. The digested MYPT1 was self-ligated and
termed N. 14-3-3 cDNA in TM27 was subcloned into pCR2.1 TOPO vector
(Invitrogen, Carlsbad, CA) and then subcloned into pGBKT7, pFBHTa,
pGEX4T1, pDsRed2, pEGFP, and pGADT7. The entire coding region of 14-
3-3 and  were amplified from human aorta cDNA library by PCR and then
subcloned into pEGFP.
Antibodies
Rabbit anti-green fluorescent protein (GFP) polyclonal antibody, mouse anti-
14-3-3 mAb, anti-DsRed antibodies, and mouse anti-MLC mAb were pur-
chased from MBL International (Woburn, MA), Calbiochem (La Jolla, CA), BD
Biosciences (San Jose, CA), and Sigma (St. Louis, MO), respectively. Mouse
anti-smooth muscle myosin mAb was produced as described (Highashihara et
al., 1989). The mouse mAb, which specifically recognizes phospho-Serine-19
of MLC, was prepared as described (Komatsu et al., 2000). Rabbit anti-MYPT1
polyclonal antibody against the C-terminal peptide (TEDGSSKRDTQTDS:
amino acids 819–832 of Rat MYPT1) and rabbit anti-pSer472 polyclonal
antibody (VIRSAphosphoSSPRLS: amino acids 467–477 of Rat MYPT1) were
prepared by Genemed Synthesis (South San Francisco, CA) and purified by
affinity chromatography as described (Niiro et al., 2003). Alexa Flour 488
phalloidin and Texas-red phalloidin were purchased from Molecular Probes
(Eugene, OR). Rabbit anti-PP1 and anti-Myosin IIb polyclonal antibodies
were kindly supplied by Dr. Villa Moruzzi (University of Pisa, Italy) and by
Dr. R. S. Adelstein (National Institutes of Health, Bethesda, MD), respectively.
Purification of Proteins
Escherichia coli expressing glutathione S-transferase (GST)-14-3-3 were lysed
in phosphate-buffered saline (PBS) with 2 mM phenylmethylsulfonyl fluoride
(PMSF), and 10 g/ml leupeptin. The homogenate was centrifuged at
10,000  g for 20 min at 4°C, and the supernatant was subjected to reduced
glutathione (GSH)-Sepharose 4B chromatography. After extensive wash, the
GST-fusion proteins were eluted by 10 mM glutathione, 100 mM Tris-HCl, pH
8.0, 100 mM NaCl, 2 mM PMSF, and 10 g/ml leupeptin. Smooth muscle
myosin and MLCK were prepared as described (Ikebe and Hartshorne, 1985;
Ikebe et al., 1987). Xenopus oocyte calmodulin was purified as described (Ikebe
et al., 1994b). Recombinant MLCP holoenzyme was purified from coinfecting
Sf9 cells with rat His MYPT1, rat PP1, and rat M21 expressing viruses as
described (Takizawa et al., 2002). Recombinant MYPT1 was also purified
according to the same procedure. Flag MYPT1 was purified using anti-Flag
affinity chromatography and eluted with Flag peptide containing 30 mM
Tris-HCl, pH 7.5, 150 mM NaCl. His 14-3-3 was expressed in Sf9 cells and
purified by Ni-NTA chromatography according to the manufacture’s protocol
(Qiagen, Chatsworth, CA).
In Vitro Binding Assay
His MYPT1 (75 g/ml) was mixed with GST-14-3-3 (60 g/ml) or GST alone
(60 g/ml) in the buffer A containing 30 mM Tris-Cl, pH 7.5, 150 mM NaCl,
and 0.5% NP-40 for 1 h at 4°C. GSH-Sepharose was added and the solution
was further incubated for 0.5 h. Similarly, GST 14-3-3 (75 g/ml) with or
without Flag MYPT1 (60 g/ml) was incubated in the buffer A for 1 h at 4°C,
and then the mixture was further incubated with Flag agarose for 0.5 h. The
GSH-Sepharose or the Flag agarose was washed three times with buffer A.
The bound proteins were eluted and subjected to SDS-PAGE. The gel was
stained with Coomassie brilliant blue (CBB). One micromolar myosin, 2 nM
MYPT1, and 6 M 14-3-3 were mixed in 30 mM Tris-Cl, pH 7.5, 0.3 M KCl
for 3 h at 4°C, and mouse anti-myosin antibody was added and incubated for
3 h at 4°C. The mixture was further incubated for 1 h at 4°C with protein
A-Sepharose. Protein A-Sepharose was washed three times with 30 mM
Tris-Cl, pH 7.5, 0.3 M KCl, and 1% NP40 and subjected to SDS-PAGE,
followed by Western blotting. Flag MYPT1 was purified in the presence of 1
M mcLR, microcystine LR (mcLR) and used for the binding assay of MYPT1
and PP1 in the presence or absence of 14-3-3. Flag-MYPT1 (50 g/ml), PP1
(60 g/ml), and GST or GST 14-3-3 (300 g/ml) were incubated with Flag
agarose in buffer A containing 100 nM mcLR, for 1 h at 4°C. Flag agarose was
then washed with buffer A containing 100 nM mcLR, and the bound fraction
was eluted as described above.
Western Blotting
The samples were subjected to 7.5–20% gradient SDS-PAGE, and then the
proteins were transferred to nitrocellulose membrane as described (Komatsu
et al., 2000).
Immunoprecipitation
COS7 or NIH3T3 cells were washed with cold PBS three times and then
scraped in lysis buffer (50 mM Tris-Cl, pH 7.5, 50 mM NaCl, 0.1% Triton-X, 1
mM PMSF, 50 mM NaF, 10 g/ml leupeptin, and 1 M mcLR). The cells were
lysed through a 26-gauge needle and centrifuged at 14,000  g for 5 min at
4°C. Supernatants were incubated with protein A-Sepharose to absorb
nonspecific binding proteins for 1 h at 4°C, and the supernatants were
incubated with control IgG or specific antibody for 3 h at 4°C and then
further incubated with protein A-Sepharose for 1 h at 4°C. Immunopre-
cipitates were washed with lysis buffer containing 100 mM NaCl three
times and subjected for SDS-PAGE, followed by Western blotting.
Phosphatase Assay
The phosphatase assay was carried out using the phosphorylated myosin as
a substrate as described (Koga and Ikebe, 2005).
Kinase Assay and Autoradiography
Phosphorylation of smooth muscle myosin was carried out at 25°C for 60 min
with 1 mg/ml myosin in 30 mM Tris-HCl, pH 7.5, 50 mM KCl, 1 mM MgCl2,
1 mM dithiothreitol, 0.1 mM CaCl2, and 0.2 mM ATP in the presence or
absence of 100 nM mcLR. The kinase reaction was started by the addition of
cell lysate prepared as described above. The phosphorylation level of MLC
was detected by Western blotting followed by densitometry analysis.
Cell Culture and Transfection
COS7 and NIH3T3 cells were cultured with DMEM, containing 10% fetal
bovine serum. Cells were transfected using Fugene6 (Roche, Indianapolis, IN)
according to the manufacturer’s protocol.
Small Interfering RNA Transfections
Control small interfering RNA (siRNA) was purchased from Dharmacon
(Boulder, CO). siRNA sequences against Rock-I and Rock-II were also from
Dharmacon (siGenome reagents d-003536 (GCCAATGACTTACTTAGGA)
and D-004610 (GCAAATCTGTTAATACTCG), respectively. Hela cells were
transfected with 50 nM siRNA using X-tremeGene siRNA reagent (Roche).
After 72-h transfection, cells were starved for 24 h and stimulated with 25
ng/ml EGF.
Immunofluorescence staining and image processing
Immunocytochemistry was performed as described (Komatsu et al., 2000,
2002).
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RESULTS
Yeast Two-Hybrid Screening for Binding Partners of
MYPT1
To identify the novel binding partners of MYPT1, a yeast
two-hybrid screening was performed using full-length rat
MYPT1 as bait. p116Rip (Koga and Ikebe, 2005) and 14-3-3
were identified as the binding proteins of MYPT1. As shown
in Figure 1A, His MYPT1 was coprecipitated with GST-14-
3-3 but not GST alone (left panel). On the other hand, GST
14-3-3 was also coprecipitated with Flag MYPT1 using Flag
agarose (right panel). The results indicate that 14-3-3 di-
rectly binds to MYPT1. Furthermore, endogenous 14-3-3
was coimmunoprecipitated with GFP-MYPT1 (Figure 1B,
left panel) and endogenous MYPT1 was coimmunoprecipi-
tated with GFP-14-3-3 (Figure 1B, right panel). The binding
between endogenous MYPT1 and 14-3-3 in untransfected
NIH3T3 and COS7 cells was also demonstrated (Figure 1C).
Furthermore, the interaction between MYPT1 and 14-3-3
was found in smooth muscle tissues such as rabbit bladder
and porcine trachea (Figure 1E). It has been known that the
targeting proteins of 14-3-3 may interact with multiple 14-
3-3 isoforms (Freed et al., 1994; Mils et al., 2000). We exam-
ined if MYPT1 binds to other 14-3-3 isoforms. We examined
the isoforms, 14-3-3 and 14-3-3, which have the highest
(87%) and the lowest (65%) homology with 14-3-3 se-
quences, respectively. As shown in Figure 1D, GFP 14-3-3
or  bound to MYPT1 as well as GFP 14-3-3 in COS7 cells
transfected with 14-3-3, , or . However, the binding of
MYPT1-14-3-3 or  was not detected in untransfected COS7
cells (not shown) unlike 14-3-3. Therefore we concentrated
our efforts on 14-3-3 in the following experiments. It should
be noted that the binding activity was detected in the pres-
ence of a potent protein phosphatase inhibitor, mcLR, in the
lysis buffer for the immunoprecipitation experiments. The
result suggests that phosphorylation is involved in the bind-
ing between MYPT1 and 14-3-3.
Effect of 14-3-3 on MLCP Activity
As the association of MYPT1 to the catalytic subunit en-
hances the myosin phosphatase activity (Alessi et al., 1992;
Shirazi et al., 1994), we examined whether the binding of
14-3-3 to MYPT1 influences the phosphatase activity of
MLCP. The MLCP activity of the holoenzyme was measured
by using phosphorylated smooth muscle myosin by MLCK
as a substrate. As shown in Figure 2A, the phosphatase
activity of MLCP was inhibited by 14-3-3 in a dose-depen-
dent manner. Similar inhibition of the phosphatase activity
was also observed with isolated MLC as a substrate (not
shown). In contrast, 14-3-3 did not inhibit the phosphatase
activity of PP1, the catalytic subunit of MLCP (Figure 2B).
The result indicates that the inhibition of the phosphatase
activity by 14-3-3 is not due to the direct inhibition of the
catalytic subunit, but is mediated by the binding of 14-3-3
to MYPT1. Because the dissociation of MYPT1 from the
catalytic subunit is anticipated to result in the decrease in the
phosphatase activity, we examined whether MYPT1 disso-
ciates from the catalytic subunit in the presence of 14-3-3.
14-3-3 was incubated with Flag-MYPT1 and His PP1, and
then the proteins bound to Flag-affinity resin were analyzed
(Figure 3A). As expected, 14-3-3 was coeluted with Flag-
MYPT1. On the other hand, the amount of PP1 coeluted
with MYPT1 was not affected by the binding of MYPT1-14-
3-3. Interestingly, the interaction between MYPT1/PP1
and 14-3-3 in the absence of microcystin LR (mcLR), a
potent Ser/Thr phosphatase inhibitor, was not detected by
Coomassie blue staining (CBB; Figure 3B), suggesting that
phosphorylation is involved in the interaction.
We also examined the effect of 14-3-3 overexpression on
the association between MYPT1 and PP1. The cell lysates
expressing 14-3-3 were subjected to immunoprecipitation
using anti-MYPT1 antibody, followed by Western blotting.
The amount of PP1 in MLCP coimmunoprecipitated with
MYPT1 was not affected by the 14-3-3 overexpression (not
shown). These results suggest that the binding of 14-3-3 to
MYPT1 does not hamper the binding of MYPT1 to the
Figure 1. Interaction of 14-3-3 proteins with
MYPT1 in vitro (A, B, and D) and in vivo (C
and E). (A) Binding of the purified 14-3-3
with MYPT1. Left, His MYPT1 (75 g/ml) and
GST-14-3-3 60 g/ml or GST (60 g/ml)
were mixed and subjected to binding assay.
Right, GST 14-3-3 (75 g/ml) with or with-
out Flag MYPT1 (60 g/ml) were incubated
with Flag agarose. The bound proteins were
eluted and subjected to SDS-PAGE. Gels were
stained with CBB. (B) Coimmunoprecipitation
of expressed MYPT1 and 14-3-3. The ex-
pressed GFP MYPT1 or GFP 14-3-3 in COS7
cells was immunoprecipitated with control
IgG or anti-GFP antibody. Left, coimmunopre-
cipitation of 14-3-3 with GFP-MYPT1; right,
coimmunoprecipitation of MYTP1 with GFP
14-3-3. (C) Coimmunoprecipitation of endog-
enous MYPT1 and 14-3-3. Untransfected
COS7 or NIH3T3 cell lysates were used for
immunoprecipitation with control IgG, anti-
MYPT1 antibody or anti-14-3-3 antibody. (D)
Coimmunoprecipitation of expressed 14-3-3,
, and  and MYPT1. The expressed GFP 14-
3-3, , and  in COS7 cells was immunopre-
cipitated with anti-GFP antibody. The immu-
noprecipitates were subjected to Western blotting. It should be noted that the immunoprecipitation experiments were carried out in the
presence of mcLR. (E) Binding of MYPT1-14-3-3 in the smooth muscle tissues. Rabbit bladder or porcine trachea lysates were used for
immunoprecipitation with control IgG or anti-MYPT1 antibody.
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catalytic subunit. In other word, 14-3-3 induced the inhibi-
tion of MLCP activity is not due to the dissociation of
MYPT1 from the holoenzyme.
The Effect of 14-3-3 on the Binding of MYPT1 to Myosin
One of the important functions of MYPT1 is its binding
ability to myosin (Sellers and Pato, 1984), and it has been
thought that this property bears the specificity of MLCP ho-
loenzyme. Therefore, we examined the effect of 14-3-3 on the
binding activity of MYPT1 to myosin. Smooth-muscle myosin,
MYPT1, and the 14-3-3 mixture was subjected to immunopre-
cipitation using anti-myosin antibody. MYPT1 was coimmu-
noprecipitated with myosin (Figure 3C) consistent with the
previous reports (Ichikawa et al., 1996; Hirano et al., 1997;
Johnson et al., 1997). Quite interestingly, 14-3-3 markedly
inhibited the binding of MYPT1 to myosin (Figure 3C). 14-3-3
was not coimmunoprecipitated with myosin, therefore, the
inhibition of coimmunoprecipitation of MYPT1 with myosin
by 14-3-3 is not due to the competition of the MYPT1 and
14-3-3 at the binding site on the myosin molecule.
14-3-3 Affects the Localization of MYPT1 on Stress Fiber
Because the binding of 14-3-3 to MYPT1 dissociates MYPT1
from myosin in vitro, we examined whether 14-3-3 affects
MYPT1 localization in cells. To address this question, we
examined the effect of the DsRed 14-3-3 overexpression on
the MYPT1 localization in the cells. We used the 14-3-3
K49E mutant as a negative control because it has been
reported that lysine 49 of 14-3-3 is essential for the interac-
tion with targeting proteins (Zhang et al., 1997). To confirm
that 14-3-3 K49E does not bind to the targeting protein, we
performed immunoprecipitation using DsRed 14-3-3 wild-
type (WT) or K49E-transfected COS7 cells. As shown in
Figure 4A, MYPT1 was coimmunoprecipitated with 14-3-3
WT but not with the K49E mutant, suggesting that K49E
mutation abolished the binding of 14-3-3 to MYPT1. It was
shown that MYPT1 localizes at the stress fiber in COS7 cells
(Koga and Ikebe, 2005). Although the overexpression of
14-3-3 K49E did not diminish the stress fiber localization of
MYPT1, the expression of DsRed 14-3-3 WT dramatically
attenuated the stress fiber localization of MYPT1 (Figure 4B).
Approximately 65% of the tested cells showed the stress
fiber localization of MYPT1 in untransfected cells as well
as mock- or 14-3-3 K49E-transfected cells, whereas the
number of cells showing the stress fiber localization of
MYPT1 was significantly decreased in 14-3-3 WT trans-
fected COS 7 cells (Figure 4C). It should be noted that
purified 14-3-3 did not facilitate the degradation of
MYPT1 (Figure 4D). 14-3-3 overexpression also did not
have an effect of MYPT1 degradation in COS7 cells (Fig-
ure 4E). Figure 5B shows the localization of myosin II in
COS7 cells. The cells were transfected with DsRed14-3-3
WT and immunostained with anti-nonmuscle myosin IIb
antibody. The overexpression of 14-3-3 showed no effect
Figure 2. The effect of 14-3-3 on MLCP (A) or PP1 (B) activity.
Various concentrations of His 14-3-3 and 2.5 nM MLCP (A) or 30
nM PP1 (B) were mixed, and then the dephosphorylation reaction
was started by adding 0.75 M 32P-labeled myosin. The prepared
myosin was free of contaminated phosphatase activity. It should be
noted that MLCP used in this experiment was not phosphorylated.
Phosphatase assay was performed as described in Material and
Methods. Values are mean  SEM of three independent experiments
and expressed as 100% of the phosphatase activity in the absence of
14-3-3.
Figure 3. The effect of 14-3-3 on the binding of MYPT1 to PP1 or
Myosin. (A) 14-3-3 does not change the binding between MYPT1
and PP1. Flag-MYPT1 (50 g/ml), PP1 (60 g/ml), and GST or
GST 14-3-3 (300 g/ml) were incubated with Flag agarose in the
buffer A containing 100 nM mcLR and incubated for 1 h at 4°C. Flag
agarose was washed and the bound fraction was eluted and then
subjected to SDS-PAGE. Gels were stained with CBB. (B) 14-3-3 does
not interact with MYPT1/PP1 in the absence of the phosphatase
inhibitor. FLAG-MYPT1 and PP1 were incubated with or without
GST 14-3-3 and without mcLR and then subjected to pulldown
assay using FLAG agarose, followed by CBB staining. (C) 14-3-3
dissociates MYPT1 from myosin. The mixture of Myosin, MYPT1
with or without 14-3-3 were subjected to immunoprecipitation
using anti-myosin antibody. The immunoprecipitates were sub-
jected to Western blotting. Left and right, the bound and the un-
bound fractions to anti-myosin antibody, respectively.
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on the stress fiber localization of myosin IIb. The result is
consistent with the in vitro finding that 14-3-3 has no
binding activity to myosin II.
Furthermore, these results suggest that the change in the
MYPT1 localization at stress fiber by 14-3-3 in cells is
neither due to the change in stress fiber structure (Figure 5A)
nor the change in myosin II localization at the stress fiber
(Figure 5B), indicating that the function of 14-3-3 is specific
to the binding of MYPT1 to myosin, but not the disruption of
the cytoskeletal structure. These results are consistent with
the results of in vitro binding experiments and support the
idea that 14-3-3 interferes with the binding between
MYPT1 and myosin.
The Effect of 14-3-3 on Myosin II Phosphorylation in
Cells
As described above, 14-3-3 attenuated MLCP activity in
vitro. To see whether 14-3-3 affects myosin II phosphory-
lation in vivo, we determined the phosphorylation level of
myosin II in cells. The cells were transfected with DsRed
14-3-3 WT or K49E or were mock transfected. The cells were
harvested and subjected to Western blot using anti-phos-
pho-Ser19 specific MLC antibody. The phosphorylation
level of myosin II in the 14-3-3 WT-transfected cells was2.4
times higher than that of mock- or 14-3-3 K49E-transfected
cells (Figure 6, C and D). To examine whether the increase in
MLC phosphorylation is due to the increase in MLCK activ-
ity or the decrease in MLCP activity, we measured the effect
of 14-3-3 overexpression on MLC phosphorylation in the
presence and absence of the MLCP inhibitor, mcLR, using
phosphorylation site–specific antibodies against Ser19 of
MLC as a probe (Komatsu et al., 2000). The isolated myosin
II was incubated with the total cell lysates in the presence or
absence of mcLR, and MLC phosphorylation was monitored
by Western blotting and quantified by densitometry. If
MLCK activity is affected by 14-3-3, MLC phosphorylation
should be altered by 14-3-3 in the presence of mcLR. As
shown in Figure 6, A and B, MLC phosphorylation was
increased by 14-3-3 WT overexpression in the absence of
mcLR, whereas the phosphorylation was unaffected by 14-
3-3 WT overexpression in the presence of mcLR. The re-
sults suggest that 14-3-3 increased myosin II phosphoryla-
tion by affecting the phosphatase activity but not the kinase
activity.
Determination of the Element of MYPT1 Responsible for
the Binding to 14-3-3
To determine the 14-3-3 binding element of MYPT1, yeast
strain AH109 was sequentially transformed with the pG-
BKT7 vector containing various fragments of MYPT1 and
then with the pGADT7 vector containing the 14-3-3. The
transformants were subjected to nutrient selection (Figure
Figure 4. The effect of 14-3-3 overexpression on MYPT1 localiza-
tion at the stress fiber. (A) The binding between DsRed 14-3-3 WT or
K49E mutant and endogenous MYPT1. The cell lysates of COS7 cells
transfected with DsRed 14-3-3 WT or K49E or of mock-transfected
cells were used for immunoprecipitation using anti-DsRed anti-
body. The immunoprecipitates were subjected to Western blotting.
(B) Representative images of the localization of MYPT1 in the 14-3-
3–transfected cells. COS7 cells were transfected with 14-3-3 WT
or K49E or were mock transfected. MYPT1 in COS7 cells were
immunostained with anti-MYPT1 antibody and visualized by FITC-
conjugated anti-rabbit IgG (green). DsRed-conjugated 14-3-3 (red)
were visualized with DsRed fluorescence signal. The cells express-
ing DsRed-14-3-3 WT do not show the stress fiber localization of
MYPT1. Bar, 10 m. (C) Fraction of the cells showing the stress fiber
localization of MYPT1. More than 600 individual cells were counted
from three independent experiments. Results are shown as means 
SEM of triplicate experiments. (D) Effect of 14-3-3 on the MYPT1
degradation. Purified MYPT1 and 14-3-3 were incubated at 25°C for
3 hrs, then the mixture was subjected to SDS-PAGE, followed by C.B.B.
staining. (E) Effect of 14-3-3 overexpression on the MYPT1 degrada-
tion in cells. COS7 cell lysates transfected with mock 14-3-3 WT or
14-3-3 K49E were analyzed by Western blotting using anti-MYPT 1
antibodies as probes. Molecular masses were indicated on the left.
Figure 5. The effect of 14-3-3 overexpression on stress fiber (A) or
myosin II localization at the stress fiber (B). 14-3-3 was visualized
with DsRed fluorescence signal. (A) Stress fiber was identified with
Alexa-conjugated phalloidin (green). (B) Myosin was immuno-
stained with anti-Myosin IIb antibody and visualized by FITC-
conjugated anti-rabbit IgG (green). Bar, 10 m.
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7A). The N-terminal 516, but not 296 fragment, showed a
positive signal, suggesting that the region Lys297-Asn516
contains the 14-3-3 binding site. Furthermore, the vector
containing the C-terminal fragment Met377-Lys976 was
found to be positive. These results defined Met377-Asn516
to be the 14-3-3 binding site. It has been known that the
binding of 14-3-3 required phosphorylation of target protein
(Furukawa et al., 1993; Michaud et al., 1995; Muslin et al.,
1996). We examined whether MYPT1 phosphorylation is
required for the binding to 14-3-3. The cell lysate was
incubated with PP1 or mcLR and then subjected to immu-
noprecipitation followed by Western blotting. Endogenous
MYPT1 was coimmunoprecipitated with endogenous 14-
3-3 when the sample was treated with mcLR but not with
PP1 (Figure 7B). The result strongly suggests that MYPT1
phosphorylation is required for the binding to 14-3-3.
Using synthetic phosphopeptides, it was shown previ-
ously that a motif, RSXphosphoSXP (where X represent any
amino acid), is critical for the binding of target proteins to
14-3-3 (Muslin et al., 1996). We searched this motif in MYPT1
sequence and found the RSASSP sequence at Arg469-
Pro474, which lies within the 14-3-3 binding region (Figure
7A). To examine whether the Ser472 MYPT1 phosphoryla-
tion is critical for the binding to 14-3-3, we produced mu-
tant MYPT1 in which Ser472 is replaced by Ala or Asp,
respectively, and the mutants were subjected to yeast two-
hybrid assays. As shown in Figure 7A, both mutants failed
to grow in the nutrient selection plate, suggesting that
Ser472 is essential for the binding of MYPT1-14-3-3. To
further ensure this issue, GFP MYPT1 mutants were ex-
pressed in COS7 cells and the binding of the mutants to
14-3-3, as well as the binding of WT MYPT1-14-3-3 was
examined by coimmunoprecipitation assay (Figure 7C). The
amount of coimmunoprecipitated 14-3-3 was markedly di-
minished by the mutation of Ser472 to Ala or Asp, respec-
tively, indicating that Ser472 is critical for the binding of
MYPT1-14-3-3. As shown in Figure 4, 14-3-3 overexpres-
sion diminished the stress fiber localization of MYPT1. We
transfected S472A MYPT1 into COS7 cells to see whether the
mutation of MYPT1 at S472 affects the stress fiber localiza-
tion of MYPT1 in 14-3-3–overexpressing cells. As shown in
Figure 8, 14-3-3 failed to diminish the stress fiber localiza-
tion of S472A MYPT1 unlike WT MYPT1. The result is
consistent with the notion that S472 phosphorylation is crit-
ical for the binding of 14-3-3 to MYPT1.
The Phosphorylation of MYPT1 at Ser472 and Its Effect
on the Interaction between MYPT1 and 14-3-3
Because the isolated MYPT1 binds to 14-3-3, the question is
if the Ser472 of the isolated MYPT1 is phosphorylated by
endogenous kinase in Sf9 cells. To answer this question, we
produced the antibody specifically recognizing the phos-
phorylated-Ser472 of MYPT1, termed pS472 antibody. The
isolated MYPT1 was preincubated with PP1 as a negative
control because PP1 treatment diminished the binding of
MYPT1-14-3-3 (Figure 7B). The pS472 antibody recognized
the untreated MYPT1 but not the dephosphorylated MYPT1,
suggesting that the isolated MYPT1 is partially phosphory-
lated at Ser472 (Figure 9A). The result shows that the bind-
ing of 14-3-3 to isolated-MYPT1 is because of the presence of
phosphorylated MYPT1 at Ser472. The Ser472 phosphoryla-
tion level of MYPT1 was significantly increased by Rho-
kinase. This is consistent with previous report that Ser472 is
one of the Rho-kinase induced phosphorylation sites in vitro
(Kawano et al., 1999). It should be noted that pS472 antibody
did not recognize Ser472A MYPT1 phosphorylated by Rho-
kinase. These results demonstrate that the pS472 antibody is
specific to the phosphorylated Ser472 of MYPT1.
To see the effect of MYPT1 phosphorylation at Ser472 on
the binding to 14-3-3, MYPT1 was phosphorylated by Rho-
kinase and then subjected to GST pulldown assay using GST
Figure 6. The effect of 14-3-3 overexpression on myosin phos-
phorylation. (A) Effect of 14-3-3 WT overexpression on the MLCK
and MLCP activities. MLC phosphorylation activity in the cell ly-
sates was determined in the presence or absence of mcLR, a potent
MLCP inhibitor. DsRed 14-3-3 WT-, K49E-, or mock-transfected
COS7 cell lysates were incubated with myosin II for 60 min as
described in Materials and Methods. Phosphorylated myosin II was
subjected to SDS-PAGE, followed by Western blotting using phos-
pho-Ser19-MLC antibodies. (B) Quantitative analysis of the increase
in myosin phosphorylation by 14-3-3 WT. The relative intensities
of MLC phosphorylation were shown. The phosphorylation level by
mock-transfected cell lysates was taken as 100%. Values are mean
SEM of three independent experiments. (C) The effects of 14-3-3
overexpression on the MLC phosphorylation level. The phosphor-
ylation level was determined by Western blotting using anti-phos-
pho-specific MLC antibody. NIH3T3 cells transfected with DsRed
14-3-3 WT or K49E or mock-transfected were collected in 10% TCA.
After sedimentation at 5000  g for 5 min, the pellet was washed
with H2O three times and then subjected to SDS-PAGE followed by
Western blotting. (D) Histogram showing the increase in MLC
phosphorylation by 14-3-3. Bands of Western blotting were sub-
jected to densitometry. Values are mean  SEM of three indepen-
dent experiments. The phosphorylation levels (signal of anti-phos-
pho-MLC/signal of anti-pan-MLC) in mock-transfected cells were
taken as 100%.
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14-3-3. The binding of MYPT1-14-3-3 was increased by
MYPT1 phosphorylation (Figure 9B). Because it is known
that Rho-kinase phosphorylates T641 and T799 of MYPT1,
we examined whether MYPT1 phosphorylation at these sites
affects the binding of 14-3-3 to MYPT1. The mutation of
MYPT1 at T641 and T799 (T641A/T799A MYPT1) did not
significantly influence the phosphorylation-dependent bind-
ing of MYPT1-14-3-3, while the additional mutation at
Ser472 to Ala diminished the binding of MYPT1-14-3-3.
These results indicate that Thr641 and Thr799 are not re-
sponsible for the binding of MYPT1-14-3-3.
An important issue is whether or not Ser472 MYPT1 phos-
phorylation is regulated by agonist stimulation in cells, un-
like Thr641 MYPT1 phosphorylation(Niiro et al., 2003). We
examined a change of Ser472 phosphorylation after EGF
stimulation, which activates the RhoA-signaling path-
way(Koga and Ikebe, 2005). Figure 9C shows that EGF stim-
ulation significantly increased Ser472 phosphorylation in
cells, unlike the Thr641 site. EGF-induced Ser472 phosphor-
ylation was abolished by Y-27632, a Rho-kinase specific
inhibitor (Figure 9D). Consistently, immunoprecipitation as-
say using anti-14-3-3 antibody revealed that EGF stimula-
tion up-regulated the binding of 14-3-3 to MYPT1 in cells
correlated with the increase in Ser472 phosphorylation, and
this binding was dramatically inhibited by Y-27632 (Figure
9E). Furthermore, the elimination of Rho-kinase I and II in
cells by siRNA treatment significantly decreased the phos-
phorylation level of Ser472 MYPT1 and MLC (Figure 9F).
These results suggest that Rho-kinase is involved in the
phosphorylation of MYPT1 at Ser472. It should be noted that
the EGF-induced increase in the Thr799 MYPT1 phosphor-
ylation was not notably changed by the elimination of Rho-
kinase (Figure 9F). Next we performed an in vitro phospha-
tase assay using WT MLCP and T641A/T799A MLCP to see
if the effect of 14-3-3 on the MLCP activity is influenced by
the possible phosphorylation of these sites (Figure 9G). Both
WT MLCP and T641A/T799A MLCP activities were simi-
larly inhibited by 14-3-3. Taking these results together, we
concluded that Rho-kinase is involved in Ser472 MYPT1
phosphorylation and regulates the binding of MLCP to 14-
3-3 and MLC phosphorylation in cells.
DISCUSSION
In the present study, we found that 14-3-3 directly binds to
MYPT1. It has been shown that 14-3-3 can interact with
various proteins and influence the localization of target mol-
ecules and/or regulate the enzymatic activity (Aitken, 1995;
Fu et al., 2000; Muslin and Xing, 2000; van Hemert et al., 2001;
Tzivion and Avruch, 2002; Aitken, 2006). We found that
14-3-3 attenuates the phosphatase activity of MLCP, but not
the catalytic subunit. Because the binding of 14-3-3 to MYPT1
does not interfere with the intersubunit binding of the MLCP
holoenzyme, the 14-3-3–induced decrease in the phosphatase
activity would be due to the change in the conformation at the
binding sites between MYPT1 and the catalytic subunit. It is
known that MYPT1 significantly increases the myosin phos-
phatase activity of PP1 and that the Rho-kinase induced
phosphorylation attenuates the elevated phosphatase activ-
ity without dissociation of MYPT1 from the holoenzyme
(Feng et al., 1999). These results suggest that the inhibition
mechanism of MYPT1 by 14-3-3 is similar to the inhibition
by MYPT1 phosphorylation in which the inhibition is
achieved by attenuating the activator function of MYPT1. It
is plausible that the binding of 14-3-3 to MYPT1 changes
the binding interface between MYPT1 and PP1 thus abol-
ishing the critical interaction between MYPT1 and PP1 that
affects the catalytic activity.
Quite interestingly, we found that 14-3-3 binding to
MYPT1 induces the dissociation of MYPT1 from myosin.
Consistently, the overexpression of 14-3-3 in cells markedly
diminished the localization of MYPT1 at the stress fiber.
Because MYPT1 associates with myosin II in the stress fiber,
the result can be explained by the finding that the binding of
14-3-3 to MYPT1 induces dissociation of MYPT1 from my-
osin II in stress fiber. Because 14-3-3 does not break the
MLCP subunit structure, it is anticipated that 14-3-3 disso-
ciates the MLCP holoenzyme from myosin by breaking the
interaction between MYPT1 and myosin. The dissociation of
MLCP from myosin is expected to result in decrease in the
dephosphorylation rate of myosin, thus increasing the my-
osin phosphorylation level. It should be noted that 14-3-3
inhibited the phosphatase activity of MLCP even though the
Figure 7. The determination of the element
of MYPT1 responsible for the binding to 14-3-
3. (A) Schematic diagram of rat MYPT1 in-
cluding 14-3-3 protein binding motifs and, its
deletion constructs used in this study. AH109
Yeast strain was simultaneously transformed
with a pGBKT7 fused to MYPT1 cDNA and a
pGADT7 fused to 14-3-3 cDNA. The strain
was also cotransformed with a pGADT7 fused
to MYPT1 cDNA and a pGBKT7 fused to 14-
3-3 cDNA. Transformants were streaked on
the plate lacking leucine, tryptophan, and then
the produced colonies were restreaked on the
plate lacking leucine, tryptophan and histi-
dine containing X--Gal on the surface of the
plate. (B) Effect of the phosphorylation of
MYPT1 on the binding to14-3-3. The COS7
cell lysates were treated with 75 nM PP1 or
100 nM mcLR for 30 min at 25°C. The lysates
were used for immunoprecipitation with anti-
14-3-3 antibody and then subjected to West-
ern blotting. (C) Effect of the mutation of S472
MYPT1 on the binding to 14-3-3. COS7 cells
were cotransfected with GFP MYPT1 (WT),
(S472A) or (S472D), and 14-3-3, respectively.
The lysates were immunoprecipitated with
anti-GFP antibody in the presence of 100 nM mcLR and the precipitates were subjected to Western blotting.
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isolated MLC was used as a substrate, suggesting that the
inhibition of the phosphatase activity in vitro is not directly
due to the dissociation of MLCP from myosin. Therefore, it
is anticipated that 14-3-3 inhibits MLCP activity by dual
mechanism in cells, i.e., the decrease in the enzymatic activ-
ity and the segregation of the substrate (myosin) from the
enzyme (MLCP). Supporting this view, we actually found
that the expression of 14-3-3 increased the MLC phosphor-
ylation level in cells (Figure 6), and this is due to the down-
regulation of myosin phosphatase, but not the activation of
myosin kinase activity.
It has been puzzling that although isolated MLCP strongly
binds to myosin, the majority of MLCP in cell is localized
throughout cytosol, and only a part of the MLCP colocalized
with the structure where myosin II is present, such as stress
fiber (Murata et al., 1997). The present results suggest that
14-3-3 is at least, in part, responsible for the cytosolic
localization of MLCP. The question is how 14-3-3 controls
MLCP localization at the myosin II–containing structure in
vivo. To address this question, we examined the effect of the
protein phosphatase treatment of MYPT1 on the binding to
14-3-3. The result suggested that the phosphorylation of
MYPT1 is critical for the binding of MYPT1-14-3-3.
Further analysis revealed that the motif RSXSXP present
in the MYPT1 sequence is responsible for the interaction
between 14-3-3 and MLCP, because 1) the mutation of S472
of MYPT1 inhibited the growth of the 14-3-3–transfected
yeast on the nutrient selection plates in yeast two-hybrid
experiments and 2) the S472A and S472D mutant of MYPT1
failed to coimmunoprecipitate with 14-3-3 in contrast to the
WT MYPT1. This view is supported by the finding that the
localization of the S472A mutant of MYPT1 at the stress fiber
in COS7 cells was not influenced by 14-3-3 expression,
whereas the stress fiber localization of WT MYPT1 was
diminished. It has been reported that 14-3-3 protein bind to
the phosphorylated proteins and the RSXSXP motif is critical
for the binding to partner proteins such as Raf (Muslin et al.,
1996) and CDC25 (Zha et al., 1996; Mils et al., 2000). The
present result agrees with the notion found in other 14-3-3
binding proteins.
Because the mutation of S472 interferes with the interac-
tion between 14-3-3 to MYPT1, the phosphorylation site
critical for the binding should be S472. To clarify this issue,
we produced the antibody that specifically recognize the
phosphorylated Ser472 of MYPT1. The antibody recognized
MYPT1 phosphorylated by Rho-kinase, but not MYPT1 de-
phosphorylated by PP1. Furthermore, the mutation of
Ser472 completely abolished the interaction of these antibod-
ies with MYPT1. These results indicate that the produced
antibodies are specific to the phosphorylated Ser472 of
MYPT1. Interestingly, the isolated MYPT1 was recognized
with anti-phospho-Ser472 antibody, indicating that MYPT1
expressed in Sf9 cells is partially phosphorylated at Ser472.
Therefore, it is thought that the binding of 14-3-3 to the
expressed MYPT1 is because of the presence of phosphory-
lated MYPT1 at Ser472.
It is interesting that S472D MYPT1 also failed to interact
with 14-3-3, indicating that the introduction of the negative
charge at the position of Ser472 does not mimic the phos-
phorylation effect. The introduction of the acidic residues
has been used to determine the phosphorylation sites of
proteins assuming that the negative charges of acidic amino
acid resemble the phosphate moiety, thus mimicking the
phosphorylation effect. However, the 3D position of the
phosphate moiety is different from that of the side chains of
the acidic residues, and it is anticipated that the acidic
residues do not always mimic the phosphorylation effect. In
fact, the replacement of Ser19 of MLC by Asp does not
mimic the phosphorylation effect on myosin motor function,
although it mimics the phosphorylation effect on filament
formation of myosin (Ikebe et al., 1994a; Kamisoyama et al.,
1994). It was also shown that mutation of S175 of calponin to
Asp shows a dephosphorylated phenotype rather than the
phosphorylated phenotype (Tang et al., 1996). We think that
the introduction of a phosphate moiety at a proper 3D
configuration is essential to induce the binding of MYPT1-
14-3-3.
Using the phosphorylation site specific antibody against
Ser472, we found that Rho-kinase phosphorylates Ser472 of
MYPT1 in cells, and this is consistent with the previous
report that Rho-kinase can phosphorylate this site in vitro
(Kawano et al., 1999). Furthermore, we found that Ser472
MYPT1 phosphorylation is increased by EGF stimulation,
and the Ser472 phosphorylation is inhibited by the Rho-
kinase inhibitor. Therefore, it is plausible that the activation
Figure 8. The effect of 14-3-3 overexpression on the localization
of MYPT1 (WT) and MYPT1 (S472A) at stress fiber. (A) Represen-
tative images of GFP MYPT1 (WT) and MYPT1 (S472A) in the cells
transfected with 14-3-3. Note that DsRed 14-3-3 diminished stress
fiber localization of MYPT1 (WT) but not MYPT1 (S472A). The
untransfected cell showed normal stress fiber localization of MYPT1
(WT; top panel). COS7 cells were cotransfected with GFP-MYPT1
(WT) or (S472A) and DsRed 14-3-3 or were mock transfected. Bar,
10 m. (B) Fraction of the cells showing stress fiber localization of
MYPT1. The stress fiber localization of WT MYPT1 was significantly
diminished by 14-3-3, but that of S472A MYPT1 was not affected.
More than 300 individual cells were observed from three indepen-
dent experiments. Values are mean  SEM of three independent
experiments.
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of the RhoA pathway induces the phosphorylation of
MYPT1 at Ser472, which enhances the interaction between
14-3-3 and MYPT1. Surprisingly, the elimination of endog-
enous Rho-kinase I and II by Rho kinase–specific siRNA did
not affect EGF-induced Thr799 MYPT1 phosphorylation,
whereas the siRNA-induced gene silencing diminished both
the EGF-induced increase in the Ser472 MYPT1 phosphory-
lation and MLC phosphorylation. Consistently, 14-3-3 in-
hibited T641A/T799A MLCP activity to the same potency as
the inhibition of WT MLCP activity. These results indicate
that Ser472 but not Thr641/Thr799 MYPT1 phosphorylation
is predominantly regulated by Rho-kinase in the EGF sig-
naling, thus regulating MLCP activity and MLC phosphor-
ylation. Further studies are required to clarify the pathways
responsible for the regulation of MYPT1 phosphorylation at
Thr641/Thr799 sites.
On the basis of the present study, we propose the follow-
ing scenario for the regulatory function of 14-3-3/MYPT1.
The agonist stimulates RhoA/Rho-kinase pathway, which
phosphorylates Ser472 MYPT1. The phosphorylation en-
hances the interaction between 14-3-3 and MYPT1, which
results in the decrease in the myosin dephosphorylation rate
due to the inhibition of MLCP activity and the dissociation
of MLCP from myosin, thus increasing in myosin phosphor-
Figure 9. Agonist (EGF) induces the phos-
phorylation of MYPT1 at Ser472 by Rho-ki-
nase in the cells, which enhances the binding
of MYPT1-14-3-3. (A) Specificity of the phos-
phorylation site–specific antibody against
Ser472 of MYPT1. The purified MYPT1 (Un)
was dephosphorylated by PP1 (DP) or phos-
phorylated by Rho-kinase (P). Samples were
subjected with SDS-PADE, followed by West-
ern blotting using pSer472 and pan MYPT1
antibodies, respectively. (B) The effect of
MYPT1 phosphorylation by Rho-kinase on the
binding to 14-3-3. MYPT1 WT, T641A/
T799A, or S472A/T641A/T799A mutant was
phosphorylated by Rho-kinase, incubated
with GST 14-3-3, and then subjected to GST-
pulldown assay. (C) EGF-induced phosphory-
lation of MYPT1 at Ser472 in cells. Hela cells
were stimulated with 25 ng/ml EGF after se-
rum starvation for 24 h. MYPT1 phosphoryla-
tion levels were analyzed by Western blotting
using the indicated antibodies. (D) Effect of
Y-27632 on the EGF-induced MYPT1 phos-
phorylation. MYPT1 phosphorylation levels in
Hela cells was examined by Western blotting
with or without pretreatment with 10 M
Y-27632 before the EGF stimulation. (E) Inhib-
itory effect of Y-27632 on the EGF-induced
binding of MYPT1-14-3-3. Hela cells treated as
described in D were subjected to the immuno-
precipitation assay in the presence of mcLR
and Y-27632 with anti-14-3-3 antibody. The
samples were then examined by Western blot-
ting. (F) Silencing of Rho-kinase I and II inhib-
ited Ser472 MYPT1 phosphorylation and MLC
phosphorylation. Hela cells were transfected
with control or Rho-kinase I and II siRNA for
72 h and stimulated with 25 ng/ml EGF for 5
min after the serum starvation for 24 h. P,
phosphorylated; Un, untreated; DP, dephos-
phorylated. (G) Effect of 14-3-3 on the WT
MLCP and T641A/T799A MLCP activities. A fixed amount of 14-3-3 (0.06 M) was added to WT MLCP and T641A/T799A MLCP,
respectively, in the phosphatase assay solution. A phosphatase assay was performed as described in Materials and Methods. Values are mean
SEM of three independent experiments and expressed as 100% of the phosphatase activity in the absence of 14-3-3.
Figure 10. A model for the regulation of MLCP by 14-3-3. MLCP is
associated with myosin II via MYPT1/myosin II heavy-chain inter-
action. Once MYPT1 is phosphorylated at Ser472, 14-3-3 binds to
MYPT1, dissociating MLCP from myosin II heavy chain and de-
creasing the myosin phosphatase activity.
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ylation (Figure 10). It has been known that the activation of
RhoA pathway increases myosin phosphorylation due to the
inhibition of myosin dephosphorylation activity (Kimura et
al., 1996). The present study reveals the novel mechanism of
RhoA-dependent MLCP regulatory mechanism and sug-
gests that the binding of 14-3-3 to MYPT1 is, in part, respon-
sible for the down-regulation of MLCP, thus enhancing my-
osin II–based motor activity in mammalian cells.
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